Brahim BELBELLAA
Associate Director, Research and Novel Vector Technologies at Adverum Biotechnologies - Redwood City, California, US
Brahim BELBELLAA's Colleagues at Adverum Biotechnologies
Mehdi Gasmi
chief science and technology officer, senior vice president pharmaceutical development
Brahim BELBELLAA's Contact Details
(650) 656-9323
Adverum Biotechnologies
Brahim BELBELLAA's Company Details
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.